MAP2K7 and metastatic melanoma: Drug resistance to B-Raf inhibitors was partially palliated and delayed when the B-Raf/MEK combined therapy was introduced, but the occurrence of resistance to drug therapy is still the main limitation of B-Raf monotherapy or combined B-Raf/MEK inhibitor therapy for advanced and metastatic melanoma [61].